
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Free Report) – Equities research analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Orchestra BioMed in a report issued on Friday, November 13th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($1.37) per share for the year, up from their previous estimate of ($1.52). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q4 2026 earnings at ($0.36) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.32) EPS, Q4 2027 earnings at ($0.32) EPS and FY2027 earnings at ($1.29) EPS.
Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.10. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.13 million. Orchestra BioMed had a negative net margin of 182.50% and a negative return on equity of 186.93%.
OBIO has been the subject of several other reports. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a report on Friday, October 23rd. BTIG Research increased their price target on Orchestra BioMed from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen raised Orchestra BioMed from a “sell” rating to a “hold” rating in a report on Saturday. B. Riley Financial boosted their price objective on Orchestra BioMed from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Finally, Weiss Ratings upgraded Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.29.
Read Our Latest Analysis on OBIO
Orchestra BioMed Trading Down 1.8%
Shares of NASDAQ OBIO opened at $7.12 on Tuesday. The company has a debt-to-equity ratio of 4.58, a current ratio of 7.25 and a quick ratio of 8.24. The firm’s 50-day moving average price is $5.90 and its two-hundred day moving average price is $4.64. Orchestra BioMed has a 52-week low of $3.46 and a 52-week high of $7.45.
Hedge Funds Weigh In On Orchestra BioMed
Several hedge funds and other institutional investors have recently made changes to their positions in OBIO. Goldman Sachs Group Inc. grew its holdings in Orchestra BioMed by 112.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 382,160 shares of the company’s stock worth $2,377,000 after buying an additional 202,554 shares in the last quarter. Jump Financial LLC acquired a new stake in Orchestra BioMed in the 3rd quarter valued at approximately $136,000. Empowered Funds LLC acquired a new stake in Orchestra BioMed in the 3rd quarter valued at approximately $450,000. HighTower Advisors LLC raised its stake in Orchestra BioMed by 8.7% during the 3rd quarter. HighTower Advisors LLC now owns 38,462 shares of the company’s stock valued at $239,000 after acquiring an additional 3,087 shares in the last quarter. Finally, Daytona Street Capital LLC raised its stake in Orchestra BioMed by 27.7% during the 3rd quarter. Daytona Street Capital LLC now owns 123,148 shares of the company’s stock valued at $744,000 after acquiring an additional 26,750 shares in the last quarter. 53.20% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other Orchestra BioMed news, insider Darren Sherman sold 15,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $5.74, for a total transaction of $86,100.00. Following the completion of the transaction, the insider directly owned 1,104,402 shares of the company’s stock, valued at $6,339,267.48. The trade was a 1.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Pacitti bought 20,000 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was purchased at an average price of $5.00 per share, with a total value of $100,000.00. Following the transaction, the director owned 74,750 shares in the company, valued at $373,750. The trade was a 36.53% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 58,000 shares of company stock valued at $288,560 and have sold 45,000 shares valued at $255,600. 7.50% of the stock is owned by insiders.
Orchestra BioMed Company Profile
Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices. The company’s lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.
Featured Stories
- Five stocks we like better than Orchestra BioMed
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
